+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Generex Biotechnology Corp (GNBT) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 52 Pages
  • December 2021
  • GlobalData
  • ID: 4437314
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Generex Biotechnology Corp (GNBT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:


  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights


Generex Biotechnology Corp (Generex) carries out the research, development and commercialization of drug delivery systems and technologies. It developed a proprietary platform technology to deliver drugs into the human body through the oral cavity. The company’s proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using proprietary RapidMist device. Generex through its subsidiary, Antigen Express, has expanded its focus to include immunomedicines incorporating proprietary vaccine formulations for the treatment of infectious, malignant, allergic and autoimmune diseases. Generex is headquartered in Miramar, Florida, the US.

Generex Biotechnology Corp Key Recent Developments


May 06,2021: Generex Biotechnology subsidiary NuGenHealth contracts with Florida Health Care Associates to provide Remote Patient Monitoring (RPM) Services
Jan 08,2021: Generex Biotechnology Announces Investor Conference Call Scheduled for Friday February 5, 2021 at 9:00 AM
Oct 06,2020: Generex Subsidiary NuGenerex Immuno-Oncology announces world class Scientific Advisory Board appointments for its COVID-19 vaccine development program
Sep 25,2020: Generex Biotechnology subsidiary NuGenHealth contracts with Paradise Valley Family Medicine to provide Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) services
Aug 26,2020: Generex Biotechnology announces call-in details and updated agenda for shareholder conference call on Wednesday, August 26th, 2020 at 9:30 AM Eastern

Key benefits of buying this profile include:


You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Generex Biotechnology Corp - Key Facts
  • Generex Biotechnology Corp - Key Employees
  • Generex Biotechnology Corp - Key Employee Biographies
  • Generex Biotechnology Corp - Major Products and Services
  • Generex Biotechnology Corp - History
  • Generex Biotechnology Corp - Company Statement
  • Generex Biotechnology Corp - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries

Section 2 - Company Analysis
  • Company Overview
  • Generex Biotechnology Corp - Business Description
  • Generex Biotechnology Corp - Corporate Strategy
  • Generex Biotechnology Corp - SWOT Analysis
  • SWOT Analysis - Overview
  • Generex Biotechnology Corp - Strengths
  • Generex Biotechnology Corp - Weaknesses
  • Generex Biotechnology Corp - Opportunities
  • Generex Biotechnology Corp - Threats
  • Generex Biotechnology Corp - Key Competitors

Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
  • Generex Biotechnology Corp, Recent Deals Summary

Section 5 - Company’s Recent Developments
May 06, 2021: Generex Biotechnology subsidiary NuGenHealth contracts with Florida Health Care Associates to provide Remote Patient Monitoring (RPM) Services
Jan 08, 2021: Generex Biotechnology Announces Investor Conference Call Scheduled for Friday February 5, 2021 at 9:00 AM
Oct 06, 2020: Generex Subsidiary NuGenerex Immuno-Oncology announces world class Scientific Advisory Board appointments for its COVID-19 vaccine development program
Sep 25, 2020: Generex Biotechnology subsidiary NuGenHealth contracts with Paradise Valley Family Medicine to provide Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) services
Aug 26, 2020: Generex Biotechnology announces call-in details and updated agenda for shareholder conference call on Wednesday, August 26th, 2020 at 9:30 AM Eastern
Aug 17, 2020: Generex Biotechnology announces agenda for shareholder conference call on wednesday August 26th, 2020 at 9:30 am
Jul 10, 2020: Generex Biotechnology announces corporate update and investor conference call: NuGenerex Immuno-Oncology today friday July 10, 2020 at 4:15 PM
Apr 17, 2020: Generex Biotechnology receives a letter of support from WCCT Global
Apr 14, 2020: Generex Biotechnology provides update on the development of an Ii-Key- SARS-CoV-2 peptide vaccine against the covid-19 pandemic
Apr 06, 2020: Generex Biotechnology CEO offers an open letter to shareholders and provides an update on corporate response to the COVID-19 pandemic
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About The Publisher
  • Contact The Publisher
  • Disclaimer

List of Tables
  • Generex Biotechnology Corp, Key Facts
  • Generex Biotechnology Corp, Key Employees
  • Generex Biotechnology Corp, Key Employee Biographies
  • Generex Biotechnology Corp, Major Products and Services
  • Generex Biotechnology Corp, History
  • Generex Biotechnology Corp, Subsidiaries
  • Generex Biotechnology Corp, Key Competitors
  • Generex Biotechnology Corp, Ratios based on current share price
  • Generex Biotechnology Corp, Annual Ratios
  • Generex Biotechnology Corp, Annual Ratios (Cont...1)
  • Generex Biotechnology Corp, Annual Ratios (Cont...2)
  • Generex Biotechnology Corp, Interim Ratios
  • Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
  • Generex Biotechnology Corp, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios

List of Figures
  • Generex Biotechnology Corp, Performance Chart (2016 - 2020)
  • Generex Biotechnology Corp, Ratio Charts
  • Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Generex Biotechnology Corp, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

Companies Mentioned

A selection of companies mentioned in this report includes:

  • StageZero Life Sciences Ltd
  • Sernova Corp
  • Novo Nordisk AS
  • Novavax Inc
  • Merck & Co Inc
  • MedImmune, Inc.
  • GlaxoSmithKline Plc
  • Eli Lilly and Co
  • Aptose Biosciences Inc
  • Apotex Inc
  • Ambrilia Biopharma Inc